Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04201457
Recruitment Status : Recruiting
First Posted : December 17, 2019
Last Update Posted : March 11, 2021
Sponsor:
Information provided by (Responsible Party):
Pediatric Brain Tumor Consortium

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 28, 2025
Estimated Study Completion Date : February 28, 2027